Acknowledgements
P.
BNT211-01 was sponsored and funded by BioNTech. We thank the patients and their families for making this trial possible. We thank P. Young, K. Vemuri and J. Hinson for statistical support; P. Oehm for support with pharmacokinetic/pharmacodynamic analyses; S. Wöll, A. Feldner and S. Brachtendorf for histological analyses; K. Star and S. Wirsching for clinical operations support; I. Bigalke and P. Schröder for IMP manufacturing; M. PinoClaveria and S. Engel for CAR-T characterization; O. Lysenko for medical monitoring support; G. Rauser for project management support; and K. Reinhard for her role in the development of the IMPs. We also thank the Safety Review Committee and the clinical trial teams.